Brokers Set Expectations for TLSI Q3 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for TriSalus Life Sciences in a report released on Wednesday, September 9th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.12) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. HC Wainwright also issued estimates for TriSalus Life Sciences’ Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $1.02 EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.67.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock opened at $4.70 on Friday. The firm has a market capitalization of $289.43 million, a PE ratio of -3.62 and a beta of 0.44. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The firm’s 50-day simple moving average is $4.75 and its 200 day simple moving average is $4.33. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences in the 1st quarter valued at about $187,000. Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Key TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: HC Wainwright’s forecasts point to improving profitability over time. The firm projects EPS losses of $0.31 for fiscal 2026 and $0.28 for fiscal 2027, followed by positive EPS of $0.09 in 2028, $0.57 in 2029 and $1.02 in 2030. This creates a long-term growth narrative for investors. TriSalus Life Sciences analyst estimates
• Positive Sentiment: The analyst expects quarterly losses to narrow from $0.12 per share in the third quarter of 2026 to $0.02 per share in the fourth quarter of 2027, suggesting gradual operating improvement.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.